Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India

PARIS and NEW DELHI, India, Sept. 20 /PRNewswire/ -- Cellectis bioresearch, the specialist in genome customization and subsidiary of Cellectis (Alternext: ALCLS), and Helix BioService & Consultants Pvt Ltd (Helix Biocon), today announced that they will join forces for the promotion of Cellectis bioresearch's meganuclease-based products and services in India. Helix Biocon is a young company comprised of professionals with proven expertise in the field of Life sciences, pharmaceuticals and drug discovery research. The companies will pool their expertise to ensure maximum availability for the innovative cellular Genome Positioning System (cGPS®) lines of products and to promote cell line engineering service for bioproduction.

"Cellectis bioresearch aims to make its products the gold standard in genome customization for the life science community throughout the world," said Luc Selig, VP Sales & Marketing at Cellectis bioresearch. "India, as a major player in bioproduction, is a key market for our cell line engineering services. This new collaboration with Helix Biocon will bring our full line of products and services to the growing Indian science community."

Cellectis bioresearch's portfolio today offers over 100 product references, addressing the major needs for genome customization of the life science community.

"We believe Cellectis bioresearch has exciting product lines for top level researchers in pharmaceutical, drug discovery and academia and is poised to redefine genome engineering," said R. Agarwal, Business Director of Helix Biocon. "By providing the cGPS® lines of products coupled with Cellectis' technology transfer and partnership services, Helix Biocon shall be able to offer game changing tools to our Indian customers to assist them in the pursuit of tomorrow's most important scientific discoveries."

About Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on meganucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies. The kits can be purchased online from www.cellectis-bioresearch.com. Check the website for more information.

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over Euro 70 million in funding since inception.

More information at www.cellectis.com

Follow Cellectis on Twitter at www.twitter.com/cellectis

About Helix Biocon

Helix BioService & Consultants Pvt. Ltd, New Delhi, India, professionally managed by a young team which has rich experience in the field of academia, drug discovery and pharmaceutical Research, (Instrumentation, Software, Reagents and Services), and other technologies with a vision to expand into new areas of Healthcare. Helix Biocon works with many global companies who support academia, drug discovery and pharmaceutical research to maintain their competitive edge in India through innovative technology and value added services for accelerating the healthcare research.

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa n 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

SOURCE Cellectis bioresearch

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED